TNFRSF1A and myeloid sarcoma: However, despite strong preclinical data supporting TNF neutralization as a therapeutic for MS, relapsing remitting patients treated with lenercept, a soluble TNFR1 IgG fusion protein, developed increased relapse rates and worsening of neurological functions [43].